Needham analyst Serge Belanger downgrades Clarus Therapeutics Hldgs (NASDAQ:CRXT) from Buy to Hold.
Will iPhone 14 Enhancements Be ‘Mind-Blowing’ Or ‘Modest’? Gurman Weighs In Ahead Of Sept. 7 ‘Far Out’ Event
Apple, Inc.’s (NASDAQ: AAPL) “Far Out” hardware launch event is only a few days away, and rumor mills are working overtime over what the newest iteration of the company’s flagship iPhone product holds for users.
